Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 4/20 | 0.38 |
| ▸ | PDE4A | P27815 | 3/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16229993 | 1.00 | CYP1A2 (0.41) | CYP1A2NAAAPDE4APDE4BPDE4C | |
| SCHEMBL5105272 | 1.00 | CYP1A2 (0.41) | CYP1A2NAAAPDE4APDE4BPDE4C | |
| SCHEMBL5385959 | 0.94 | CYP1A2 (0.47) | CYP1A2NAAAPDE4APDE4BPDE4C | |
| SCHEMBL9342752 | 0.94 | CYP1A2 (0.47) | CYP1A2NAAAPDE4APDE4BPDE4C | |
| SCHEMBL5385955 | 0.94 | CYP1A2 (0.47) | CYP1A2NAAAPDE4APDE4BPDE4C | |
| SCHEMBL29632519 | 0.92 | CYP1A2 (0.46) | CYP1A2NAAAPDE4APDE4BPDE4C | |
| SCHEMBL28437706 | 0.92 | CYP1A2 (0.46) | CYP1A2NAAAPDE4APDE4BPDE4C | |
| SCHEMBL1777044 | 0.88 | — | — | |
| SCHEMBL1777117 | 0.88 | — | — | |
| SCHEMBL1202062 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456211-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070155792-A1 | Peptide Deformylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20060025412-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1370258-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1363623-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6897233-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040097732-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-05-20 | — | — | US | disclosed |
| US-20040077856-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-04-22 | — | — | US | disclosed |
| EP-1363623-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1370258-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1370258-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1363623-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070654-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002070540-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155792-A1 | Peptide Deformylase Inhibitors | PDF, PEPD, DPEP1 | CYP1A2 4557/4885NAAA 1042/4885PDE4A 976/4885 |
| US-20040097732-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | CYP1A2 4557/4885NAAA 1042/4885PDE4A 976/4885 |
| US-20040077856-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | CYP1A2 4557/4885NAAA 1042/4885PDE4A 976/4885 |
| US-20060025412-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | CYP1A2 4557/4885NAAA 1042/4885PDE4A 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.